Biorestorative Therapies (BRTX) to Post Earnings on Tuesday

Biorestorative Therapies (NASDAQ:BRTX) is projected to issue its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $0.60 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:30 PM ET.

Biorestorative Therapies (NASDAQ:BRTX) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.01. Biorestorative Therapies had a negative net margin of 3,088.27% and a negative return on equity of 508.42%. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.31 million. On average, analysts expect Biorestorative Therapies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Biorestorative Therapies Trading Up 8.1%

BRTX traded up $0.02 during trading on Tuesday, hitting $0.21. 122,863 shares of the company’s stock were exchanged, compared to its average volume of 8,445,541. Biorestorative Therapies has a 1 year low of $0.16 and a 1 year high of $1.89. The stock has a 50 day moving average price of $0.36 and a 200 day moving average price of $0.40. The firm has a market cap of $5.45 million, a P/E ratio of -0.20 and a beta of 0.79.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BRTX. Citadel Advisors LLC purchased a new stake in Biorestorative Therapies during the 3rd quarter worth approximately $152,000. DRW Securities LLC acquired a new stake in shares of Biorestorative Therapies during the fourth quarter worth approximately $55,000. Finally, Virtu Financial LLC grew its position in shares of Biorestorative Therapies by 102.4% during the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after buying an additional 12,319 shares in the last quarter. Institutional investors and hedge funds own 69.38% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Wednesday, May 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Biorestorative Therapies presently has a consensus rating of “Sell”.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.